Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Role of Neurodegeneration in Treatment Resistant Schizophrenia With GFAP and S100B

NCT05257720 is registered in ClinicalTrials.gov with Istanbul Saglik Bilimleri University as lead sponsor.

NCT NCT05257720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05257720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Role of Neurodegeneration in Treatment Resistant Schizophrenia With GFAP and S100B
Lead sponsor
Istanbul Saglik Bilimleri University
Phase
Observational
Overall status
Completed
Start date
March 28, 2022
Completion date
October 1, 2022
Enrollment
178 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia